Harmony Biosciences had its Relative Strength (RS) Rating upgraded from 64 to 73 Friday — a welcome improvement, but still short of the 80 or higher score you prefer to see.
This proprietary rating tracks technical performance by showing how a stock's price action over the last 52 weeks compares to that of the other stocks in our database.
Over 100 years of market history reveals that the stocks that go on to make the biggest gains tend to have an 80 or higher RS Rating as they begin their largest climbs. See if Harmony Biosciences can continue to show renewed price strength and hit that benchmark.
When To Sell Stocks To Lock In Profits And Minimize Losses
Harmony Biosciences is building a consolidation with a 41.61 entry. See if the stock can clear the breakout price in heavy volume.
Earnings grew 48% last quarter, up from 6% in the prior report. Revenue also increased, from 16% to 20%.
Harmony Biosciences holds the No. 14 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, Exelixis and Halozyme Therapeutics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
